Advanced Oncotherapy (AVO) – Exercise of Warrants and issue of Shares

Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has today issued 34,122,682 new ordinary shares of 1p in the Company at a price of 1.1 pence per New Share pursuant to the exercise of warrants by Brahma AG. The warrants were issued on 25 September 2013 to Brahma in accordance with the share purchase agreement for ADAM SA.  Mr. Alberto Colussi, directly or indirectly through his vehicle Brahma, now controls 19.35% of the Issued Capital of AVO.

Commenting on this, Nicolas Serandour, CFO, said: “The exercise of these warrants shows the continued support and confidence of Brahma and the Colussi family which we greatly appreciate.”

Application has been made for the 34,122,682 Shares to be admitted to trading on AIM and it is expected that Admission will occur on or about 4 August 2015. The Shares will rank pari passu in all aspects with the existing ordinary shares of the Company.

Total voting rights

Following Admission, the Company’s enlarged issued share capital will comprise 1,411,161,708 ordinary shares, with voting rights. The Company does not hold any ordinary shares in treasury. Therefore the total number of ordinary shares in the Company with voting rights will be 1,411,161,708. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA’s Disclosure and Transparency Rules.

For further information, please contact: